HC Wainwright & Co. Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $36
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces Price Target of $36.